Lundbeck and Otsuka’s Rexulti has become the first drug to be approved by the FDA to treat agitation associated with Alzheimer’s disease, a common symptom of the neurodegenerative disorder. The ...

Otsuka and Lundbeck’s antidepressant Rexulti should be approved to treat Alzheimer’s disease-related agitation (AAD), according to FDA advisors – a move that could unlock a sizeable new market for the ...

Diagnostic delays of 10 to 15 years are common among people with bipolar disorder, research shows. Here’s what two people with the condition have to say about experiences that, in hindsight, they ...

Behavioral addiction involves compulsively engaging in behaviors like gambling or social media use. Warning signs include prioritizing the behavior over other activities and experiencing shame but ...